Sirio Pharma Co., Ltd.

Shenzhen Stock Exchange 300791.SZ

Sirio Pharma Co., Ltd. Inventory for the year ending December 31, 2023: USD 67.76 M

Sirio Pharma Co., Ltd. Inventory is USD 67.76 M for the year ending December 31, 2023, a 101.04% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.

Sirio Pharma Co., Ltd. Inventory for the year ending December 31, 2022 was USD 33.70 M, a -10.63% change year over year.
Sirio Pharma Co., Ltd. Inventory for the year ending December 31, 2021 was USD 37.71 M, a -7.73% change year over year.
Sirio Pharma Co., Ltd. Inventory for the year ending December 31, 2020 was USD 40.87 M, a 39.30% change year over year.
Sirio Pharma Co., Ltd. Inventory for the year ending December 31, 2019 was USD 29.34 M, a -11.48% change year over year.

Key data

Date	Inventory	Goodwill	Total Assets	Current Liabilities

Shenzhen Stock Exchange: 300791.SZ

Sirio Pharma Co., Ltd.

CEO	Mr. Peiqing Li
IPO Date	Sept. 25, 2019
Location	China
Headquarters	No.83 Taishan Road
Employees	2,610
Sector	Consumers Staples
Industries Non-Alcoholic Beverages Consumer Packaged Goods Cosmetics Personal Care Pet Food Pharmaceuticals Plastics Soft Drinks & Sodas

Description

Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplements to customers worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; various nutraceutical gummies; probiotic products; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging. Sirio Pharma Co., Ltd. was founded in 1993 and is headquartered in Shantou, China.

Key trends

Past 5 years